Clinical Trials

8 trials
RecentStart dateEnrollment
Paraproteinemias × 90 days × Clear all
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Anus Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Duodenal Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Hypopharyngeal Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Lip Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Multiple Myeloma, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Paraproteinemias, Penile Neoplasms, Peritoneal Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Central Nervous System Neoplasms, Thyroid Nodule, Endometrial Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Pfizer

Phase 2 Completed
39 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell